Taken together, we here describe the strategy to combine Nω-carbamoylation with 18F-fluoroglycosylation for the development of new 18F-labeled NT analogs with high affinity to NTS1, sufficient metabolic stability and high and specific uptake in NTS1-positive HT-29 tumors in vivo. The gene discussed is NTS; the disease is hematocrit.